Complaint alleging insider trading “in the securities of biopharmaceutical company Kadmon Holdings, Inc. in advance of Kadmon’s September 8, 2021 announcement that it had agreed to be acquired by the global biopharmaceutical company Sanofi S.A.”, of France, in the U.S. Securities and Exchange Commission v. Frank B. Glassner, described as “an executive compensation consultant”, of Novato, California, at the U.S. District Court for the Southern District of New York.
9
May 24, 2022
Frank B. Glassner
Securities and Exchange Commission
Topics
France Fraud Investment Listed Securities RegulatoryKeywords
Frank Glassner Kadmon Sanofi